What's Not In The Budget: Deficit Panel's Proposal For Rebates On Drugs Used By Dual-Eligibles
This article was originally published in The Pink Sheet Daily
Executive Summary
The president's National Commission on Fiscal Responsibility and Reform suggested that mandatory rebates for drugs used by Medicaid/Medicare dual eligibles would go a long way in offsetting a proposed "doc fix."
You may also be interested in...
CBO Keeps Idea Of Mandatory Rx Rebates For Medicare Part D Low-Income Members In Play
In a report on options for reducing the deficit, the Congressional Budget Office returns to the idea of mandating minimum rebates of 23.1% on drugs used by low-income beneficiaries, including dual eligibles, in Medicare Part D.
CBO Keeps Idea Of Mandatory Rx Rebates For Medicare Part D Low-Income Members In Play
In a report on options for reducing the deficit, the Congressional Budget Office returns to the idea of mandating minimum rebates of 23.1% on drugs used by low-income beneficiaries, including dual eligibles, in Medicare Part D.
CMS' 2012 Budget Looks To Biosimilars, Ban On Brand/Generic Deals To Offset Costs
The two legislative proposals contained in the budget seem unlikely to pass in the current Congress.